Standard BioTools Inc. Reports Q2 2026 Financial Results

What Happened

• Standard BioTools Inc. (LAB) filed a Form 8-K on August 5, 2026 to disclose a press release that reports certain financial results for the three and six months ended June 30, 2026. The press release is attached to the filing as Exhibit 99.1. The filing incorporates the press release information by reference into Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), excluding the sections titled “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.” The company’s forward-looking statement disclaimer is included.

Key Details

• Filing date: August 5, 2026; reporting period: three- and six-month periods ended June 30, 2026.
• Press release attached as Exhibit 99.1 to the Form 8-K.
• Information in the press release (except the “Full Year 2026 Revenue Outlook” and company description) is incorporated by reference into the 8-K.
• The filing includes the Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.

Why It Matters

• The 8-K provides investors with the company’s latest quarterly financial results and disclosure under Regulation FD; investors should read the attached press release to see the specific revenue, earnings or other metrics reported for Q2 2026.
• Because the “Full Year 2026 Revenue Outlook” section was not incorporated by reference, any guidance or outlook in the release may be presented separately from the portions incorporated into the 8-K—investors should note which statements are formally part of the filing.
• This filing is a timely disclosure of operating results ahead of periodic reports (e.g., 10-Q); review the press release and expect subsequent filings for audited or more detailed financial information.